Bristol-Myers Squibb SG&A increased by 4.4% to $1.79B in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 9.8%, from $1.98B to $1.79B. Over 3 years (FY 2021 to FY 2024), SG&A shows relatively stable performance with a 3.0% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryEfficiency
SignalLower is better
VolatilityStable
First reportedQ4 2013
Last reportedQ4 2025
How to read this metric
Increases may indicate aggressive marketing or expansion, while decreases often reflect cost-cutting measures or improved corporate efficiency.
Detailed definition
The sum of all direct and indirect selling expenses and all general and administrative expenses of a company. This inclu...
Peer comparison
Used to assess the 'leaness' of a company's corporate structure relative to its peers.
Metric ID:
is_selling_general_and_administrativeHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.88B | $1.79B | $2.35B | $1.83B | $1.79B | $1.93B | $2.27B | $1.76B | $1.93B | $2.00B | $2.07B | $2.37B | $1.93B | $1.98B | $2.14B | $1.58B | $1.71B | $1.79B |
| QoQ Change | — | -5.0% | +31.7% | -22.2% | -2.4% | +8.0% | +17.4% | -22.2% | +9.8% | +3.6% | +3.5% | +14.2% | -18.5% | +2.9% | +7.7% | -25.8% | +8.1% | +4.4% |
| YoY Change | — | — | — | — | -5.0% | +7.9% | -3.7% | -3.8% | +8.2% | +3.8% | -8.5% | +34.3% | -0.3% | -1.0% | +3.0% | -33.1% | -11.2% | -9.8% |
Range$1.58B – $2.37B
CAGR-1.2%
Avg YoY Growth-1.4%
Median YoY Growth-2.4%
Current Streak2 quarters growth
SG&A at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's sg&a?
- Bristol-Myers Squibb (BMY) reported sg&a of $1.79B in Q3 2025.
- How has Bristol-Myers Squibb's sg&a changed year-over-year?
- Bristol-Myers Squibb's sg&a decreased by 9.8% year-over-year, from $1.98B to $1.79B.
- What is the long-term trend for Bristol-Myers Squibb's sg&a?
- Over 3 years (2021 to 2024), Bristol-Myers Squibb's sg&a has grown at a 3.0% compound annual growth rate (CAGR), from $7.69B to $8.41B.
- What does sg&a mean?
- The day-to-day costs of running the business and marketing its products.